Abaloparatide is prescribed to treat osteoporosis in postmenopausal women who are at a high risk for fracture. It has a parathyroid hormone-related protein recommended when other drugs failed to treat osteoporosis.
Abaloparatide should not be used in patients with:
Allergy to abaloparatide
Bone-related disease such as Pagets disease
High levels of calcium or alkaline phosphatase in the blood
Cancer of bone (osteosarcoma) or in patients at increased risk of the cancer
Hyperactivity of parathyroid glands
Pregnancy and breastfeeding mothers, premenopausal women
Presence of high urinary calcium levels or calcium stones in the kidney
The recommended adult dose is 80 mcg to be given subcutaneously (just under the skin) once a day.
Abaloparatide injection comes as a solution in a prefilled pen which has to be given subcutaneously just under the skin directly into the periumbilical region (the region around the bellybutton) of the abdomen but 2 inches away from the bellybutton.
The injection site should be rotated every day but has to be administered at the same time each day.
The prefilled pen provides 30 doses offering a daily dose of 80 mcg of abaloparatide in a 40mcL of a sterile solution. The pen should be discarded after 30 days even if it contains some unused medication.
The injection should not be administered either by intravenous (into the vein) or intramuscular route.
The intake of too much alcohol or heavy smoking should be avoided because this leads to a reduction in bone mineral density resulting in more possible fractures.
The use of abaloparatide and other parathyroid hormone analogs such as teriparatide for a period of more than two years is not recommended because of the risk of developing osteosarcoma.
The patients should be given calcium and Vitamin D supplements if their dietary intake found to be inadequate.
It is necessary to give first few doses of abaloparatide injection at a place where the patient can sit or lie down in case of orthostatic hypotension (low blood pressure in the standing position).
Monitoring blood or urinary calcium levels must be carried out regularly in order to detect hypercalcemia, hypercalciuria or urolithiasis which are expected to occur in patients undergoing abaloparatide therapy.
Gastrointestinal: Nausea, pain in upper abdominal area, constipation, upset stomach
Cardiovascular: Orthostatic hypotension (sudden drop in blood pressure while standing), increase in heart rate, palpitations
Central nervous system: Headache, dizziness, vertigo
Genitourinary: Kidney stones, calcium loss in urine, blood in urine, pain while passing urine
Skin: Pain, swelling or redness at the injection site
Others: Immune-related allergic reactions, high blood calcium levels, tiredness, bone pain, increase in uric acid
Avoid injecting into the areas of bruised skin or red, scaly skin or in the area of scars or stretch marks.
Before injecting, the pen it should be allowed to come to room temperature and should be discarded if visible particles are present or the solution appears cloudy.
There is no specific antidote for abaloparatide poisoning but can be treated with appropriate measures such as discontinuation of the abaloparatide therapy hydration, and monitoring serum calcium and phosphorous levels.
The unopened abaloparatide injection pen should be stored in the refrigerator between 2°C to 8°C but not in a freezer.
After opening for first use, the injection can be stored at room temperature (20°C - 25°C) away from excess heat and moisture for a period of up to 30 days.
Keep out of reach of the children.
Subscribe to our Free Newsletters!